Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403 by Craig A. Portell, Opeyemi A. Jegede, Nina Wagner-Johnston, Grzegorz S. Nowakowski, Christopher Fletcher, Jonathon B. Cohen, Andrew M. Evens, Lori J. Rosenstein, Jeffrey W. Craig, Nishitha Reddy, Brad S. Kahl

Get full text

Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trialResearch in context by Jonathan W. Friedberg, Michael T. Brady, Myla Strawderman, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen, Patrick M. Reagan, Carla Casulo, Barbara L. Averill, Andrea Baran, Grerk Sutamtewagul, Paul M. Barr, John P. Leonard, John M. Ashton, John G. Strang, Francisco Vega, Derick R. Peterson, Loretta J. Nastoupil

Get full text

Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium by Jonathan R. Day, Melissa C. Larson, Urshila Durani, Jean L. Koff, Yucai Wang, Thomas M. Habermann, Izidore S. Lossos, Loretta J. Nastoupil, Christopher Strouse, Dai Chihara, Peter Martin, John P. Leonard, Jonathon B. Cohen, Brad S. Kahl, Jia Ruan, W. Richard Burack, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Matthew J. Maurer, Carla Casulo

Get full text

Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy by Reem Karmali, Geoffrey Shouse, Pallawi Torka, Tamara K. Moyo, Jason Romancik, Stefan K. Barta, Rahul Bhansali, Jonathon B. Cohen, Nirav N. Shah, Joanna Zurko, Vaishalee P. Kenkre, Brian Hess, Deborah M. Stephens, Lindsey Fitzgerald, Thomas Ollila, Bukky Tabiti, Ishan Roy, Shuo Ma, Jane Winter, Barbara Pro, Jonathan Moreira, Alexey V. Danilov, Kevin David, Leo I. Gordon, Narendranath Epperla

Get full text